Cancer relapse following chemotherapy has been attributed in part to the presence of cancer stem cells (CSC), which drive tumour growth and metastasis and are highly resistant to the effects of cytotoxic chemotherapy. As a result, treatment with cytotoxic chemotherapy selects for drug-resistant CSC populations that eventually drive tumour recurrence. Little is known currently regarding the role of CSC in dogs with lymphoma, nor the impact of chemotherapy on CSC populations. Therefore, we prospectively quantitated CSC populations in dogs with B-cell (BCL) and T-cell lymphoma (TCL), using tumour aspirates and flow cytometric analysis with a panel of CSC markers. In addition, in vitro studies were carried out to determine the impact of chemotherapy resistance on the stem cell phenotype and stem cell properties of lymphoma cells. We found that the percentages of tumour cells expressing CSC markers were significantly 
from progenitor cells that have undergone multiple mutations. 15, 16 Alternatively, mutations in adult cells may drive cell dedifferentiation to become more stem cell-like. [17] [18] [19] Although the concept of CSC is still not universally accepted, there is compelling evidence from multiple models that CSC can drive the growth and recurrence of primary tumours, and lead to tumour metastasis. 13, 20, 21 In addition, ablation of CSC has been shown experimentally to lead to the cessation of cancer growth, tumour regression and decreased relapse of aggressive cancer, consistent with their key role in sustaining the overall tumour cell population. [22] [23] [24] [25] The unusual nature of CSC cell division, and the presence of metabolic pathways that are associated with drug efflux, render these cells relatively resistant to chemotherapy compared with cancer daughter cells. Therefore, treatment with cytotoxic chemotherapy has been shown to selectively enrich lymphomas and leukaemias for CSC, which eventually leads to disease recurrence. [26] [27] [28] Multiple different populations of CSC have been identified in lymphomas in humans and in rodent models, using cell surface expressed molecules and functional properties to identify CSC within the much larger population of differentiated tumour cells. [29] [30] [31] Cell surface molecules used to define CSC in human lymphoma include CD20 + /CD27 + B cells for Hodgkin's lymphoma and CD45 + /CD19 + cells in mantle cell lymphoma cells. 32, 33 In human acute myeloid leukaemia, CD34 + /CD38 − cells were identified as leukaemia stem cells, 34 and one study found evidence suggesting that CD34 + /CD90 − cells were the source of leukaemia stem cells. 35 However, another group reported that CD90 expression was linked to poor prognosis and high-risk disease, 36 and CD90 has been identified as a marker of CSC in other tumour types. 37, 38 Other markers used to identify leukaemia stem cells include CD96, CD123, CD47, CD44 and CLL-1.
39-43
A widely-accepted vitro assay to identify CSC in vitro is their ability to form tumour spheres under non-adherent and serum-free or low serum cell culture conditions. 44, 45 The cells that form tumour spheres display CSC properties including resistance to chemotherapy and increased aldehyde dehydrogenase (ALDH) activity. 32, 46 The ALDH family of enzymes is responsible for detoxifying cells, metabolizing chemotherapeutic drugs, and for retinoic acid signalling to maintain the CSC phenotype. [47] [48] [49] For Hodgkin's lymphoma, a circulating population of CD20 + /CD27 + B cells with high levels of ALDH activity was found to be the source of Hodgkin and Reed-Sternberg cells. 32 We previously defined CSC populations in dogs with melanoma and osteosarcoma, but few similar analyses have not been carried out for dogs with lymphoma. 50 One such study explored the use of a side population (SP) assay for identifying canine CSC, and found that it failed to enrich for CSC populations from canine BCL cell lines and clinical samples. 51 Another group analysed the expression of 12 CSC markers primary BCL patient samples and found that Melk was highly expressed by malignant B cells compared with normal B cells. 52 The goal of the present study was to characterize CSC populations in canine BCL and TCL using a combination of surface marker expression and functional assays. Therefore, we leveraged many of the CSC properties defined in human lymphoma to evaluate canine lymphoma CSC. Studies were performed using flow cytometry and tumour aspirates from lymph nodes of 13 normal The normal dog population included eight females and five males.
Ages for normal dogs ranged from 3 to 12 years, with the average age being 8 years. The BCL patient population included 20 untreated females, 3 relapsed females, 15 untreated males and 6 relapsed males.
The TCL patient population included 2 untreated females and 7 untreated males. Ages for untreated lymphoma dogs ranged from 3 to 14 years with the average age being 9 years. The mean age difference between normal, untreated lymphoma, and relapsed lymphoma was not statistically significant ( Figure S1 , Supporting Information). 
| Collection and processing of tumour samples

| Lymphoma cell lines
The BCL canine lymphoma cell lines CLBL1 53 
| Flow cytometry
Samples were prepared for flow cytometry as described previously. To measure intracellular expression of Oct3/4, the cells were initially stained for surface markers before fixation with paraformaldehyde, and permeabilization with 0.25% saponin. Cells were then washed and immunostained with an anti-Oct3/4 APC-conjugated antibody (EM92, eBioscience).
| Generation of chemotherapy-resistant canine cell lines
Chemotherapy-resistant cell lines were generated by culturing tumour cells in the presence of a mixture of three of the four cytotoxic chemotherapy drugs (doxorubicin, vincristine, and dexamethasone), which comprise the CHOP cocktail, with the exception of cyclophosphamide. 8, 9 The concentrations of each drug in the mixture was as follows: CLBL1 cells: 845 ng/mL dexamethasone, 3 ng/mL vincristine, and 80 μg/mL dexamethasone and OSW cells: 30 ng/mL doxorubicin, 125 ng/mL vincristine, and 80 μg/mL dexamethasone).
These concentrations were selected based on IC50 values for each drug against the individual lymphoma cell lines, as determined using in vitro cell survival assays. Selection of drug-resistant cell lines was carried out by treating cell lines with chemotherapy-selection drugs, with a minimum of 80% cell death achieved after the first chemoselection treatment. Drug selection continued for 60 days until the cells were considered fully resistant, at which point the cells were over 99% viable ( Figure S2A ).
| Immunohistochemistry
Lymph node biopsies were harvested and fixed in periodate-lysine- 
| Tumour sphere assay
Matched numbers of untreated and chemotherapy-resistant OSW cells were plated in low-adherence Petri dishes (Falcon, Corning, New York) and maintained in cell culture medium alone or medium with chemotherapy. Images of the cells were then acquired with a light microscope after 3 days.
| ALDH assay
An Aldefluor kit (Stemcell Technologies, Vancouver, Canada) was used to measure ALDH activity in untreated and chemotherapy-resistant lymphoma cells. Verapamil (Sigma-Aldrich, St. Louis, MO) was used to prevent export of the fluorescent Aldefluor reagent, and DEAB (Stemcell Technologies, Vancouver, Canada) was added immediately to the negative control wells to quench the ALDH activity. 7-AAD (eBioscience)
was added prior to flow cytometric analysis for dead cell exclusion.
| Doxorubicin efflux assay
Efflux of doxorubicin by untreated and chemotherapy-resistant OSW cells was measured by flow cytometry, as described previously. 59 Briefly, cells
were re-suspended in medium alone, medium with 2 mg/mL Doxorubicin, or medium with 2 mg/mL Doxorubicin and 50 μg/mL Verapamil for a positive control of Doxorubicin inside the cells. After 1 hour at 37 C, cells were washed with medium alone or medium with Verapamil, allowed to rest for 1.5 hours at 37 C, washed a second time, then analysed by flow cytometry. 
| Statistical analysis
Statistical comparisons between those data sets with two sample groups were carried out using non-parametric t tests (MannWhitney test). Comparisons between three or more groups were carried out using ANOVA, followed by Tukey multiple means post-test.
Analyses were carried out using Prism7 software (GraphPad, La Jolla, California) and statistical significance was determined for P < 0.05.
3 | RESULTS
| Expression of CSC molecules by healthy and malignant lymphocytes
Malignant canine lymphocytes have been reported to exhibit a high forward scatter and medium side scatter properties. 58, 60 These criteria were therefore used to identify malignant lymphocytes in dogs with BCL and TCL. 58 The malignant tumour cells were further classified as 
| Immunohistochemical evaluation of CSC populations in tumour tissues
Lymph node biopsies from three normal dogs and from three dogs with BCL were evaluated using immunohistochemical (IHC) for expression of CD117 ( Figure 3A ) and Oct3/4 ( Figure 3B ). In normal lymph nodes from three dogs, expression of neither marker could be detected using IHC.
However, in tumour tissues of one dog with BCL, CSC expressing cytoplasmic CD117 and Oct3/4 could be detected, whereas in the other two tumour samples, expression was not detected using IHC. Cytoplasmic expression of Oct3/4 has previously been detected in cells that did not express other CSC markers analysed but appears to play a role in the survival of stressed cells, which is an important characteristic of CSC.
61,62
| Effects of chemotherapy on in vitro CSC selection
Previous studies have found that the percentages of CSC in certain cancers (breast, colorectal, and lung) are significantly increased following treatment with cytotoxic chemotherapy. [63] [64] [65] This phenomenon is thought to reflect selection for chemotherapy-resistant CSC, and the expanded CSC populations are associated with an overall decrease in responsiveness to subsequent chemotherapy. 66, 67 Studies were designed therefore to determine in vitro whether a similar response occurs in canine lymphoma following exposure to (2% compared with 0.1%), CD90 (31% compared with 0.1%), and Sca1
(1% compared with 0%) was noted in chemotherapy-resistant TCL cells (OSW), with CD90 exhibiting the highest degree of upregulation ( Figure 4D ).
Next, chemotherapy-resistant and -sensitive cells were evaluated for functional changes associated with CSC properties. These functional characteristics included tumour sphere formation in nonadherent culture conditions, doxorubicin efflux activity, and aldehyde dehydrogenase activity. We observed that chemotherapy-resistant OSW cells formed spheres much more readily in soft agar than chemotherapy-sensitive cells, suggesting a higher self-renewal capacity ( Figure 5A ). 45 These chemotherapy-resistant OSW cells also had significantly increased ALDH activity ( Figure 5B ). ALDH activity is important because the ALDH enzyme is important for detoxifying and metabolizing chemotherapeutic drugs, and maintaining overall cell "stemness." [47] [48] [49] Chemotherapy-selected OSW cells also effluxed doxorubicin much more efficiently than chemotherapy-sensitive OSW cells, consistent also with induction of efflux pump expression, another feature of CSC ( Figure 5C ). 68, 69 Upregulated ALDH activity and efflux of doxorubicin were also observed in chemotherapy-resistant BCL cells (1771) 
| DISCUSSION
There are a number of mechanisms invoked to account for lymphoma relapse following chemotherapy, including intrinsic drug resistance, or induced upregulation of drug efflux pumps, 70,71 drug metabolizing enzymes, 72 and drug-induced DNA damage repair mechanisms. 73 Selective enrichment of CSC has also been invoked as an explanation for tumour relapse in lymphoma, based on evidence from experimental rodent models and human trials. 26, [74] [75] [76] [77] [78] A recent study reported that BCL cell lines and cells from canine BCL patient lymph nodes showed increased expression levels of ABC transporters and genes associated with the CSC phenotype (ABCG2 and Bmi-1), but found that these characteristics did not appropriately identify CSC populations. 51 In addition, functional studies of these cells demonstrated the ineffectiveness of the SP assay to enrich for CSC populations, leading to the conclusion that other methodologies, (Figure 2 ). In TCL, the most prominent CSC subpopula- The functional properties of CSC not only contribute to longevity, but they also render these cells more resistant to radiation treatment and chemotherapy drugs, allowing them to evade the effects of cytotoxic chemotherapy. 79, 80 Thus, it would be very desirable to identify drugs or other agents that could selectively target CSC for elimination.
The ability to selectively enrich for lymphoma CSC using in vitro chemotherapy selection may provide one tool for identification of agents that more selectively target CSC. Furthermore, the ability to accurately phenotype CSC subpopulations in naive tumour samples using flow cytometry may provide a useful prognostic marker for predicting initial responses to chemotherapy as well as overall remission duration.
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https://orcid.org/0000-0002-0758-3945 FIGURE 6 Cancer stem cell marker expression by normal lymphocytes, untreated lymphoma, and relapsed lymphoma. Fine needle aspirates were collected from lymph nodes of normal dogs and from lymph nodes of dogs with B-cell lymphoma (BCL) (both untreated and relapsed) for flow cytometric analysis. The cells were stained for CD21 and CD5 to identify B cells as shown in Figure 1 , and positive staining for expression of cancer stem cell markers (CD29, CD34, CD90, CD117, Oct3/4, and Sca1) was determined with respect to cells stained with irrelevant isotype antibodies. The data were analysed using FlowJo software, and data shown are compiled from a total of 12 healthy dogs, 35 untreated BCL, and 9 relapsed BCL. Data are presented as mean AE SEM of the percentage of marker expression on lymphocytes, and statistical analysis was performed using two-tailed ANOVA, followed by Tukey's multiple means comparison. Statistically significant differences were denoted as * P < 0.05 and ****P < 0.0001
